Pyroxamide
CAS No. 382180-17-8
Pyroxamide( —— )
Catalog No. M20956 CAS No. 382180-17-8
Pyroxamide is an histone deacetylases (HDACs) inhibitor with antineoplastic properties ( HDAC1;IC50: 0.1-0.2 μM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 39 | In Stock |
|
| 10MG | 68 | In Stock |
|
| 25MG | 146 | In Stock |
|
| 50MG | 251 | In Stock |
|
| 100MG | 443 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePyroxamide
-
NoteResearch use only, not for human use.
-
Brief DescriptionPyroxamide is an histone deacetylases (HDACs) inhibitor with antineoplastic properties ( HDAC1;IC50: 0.1-0.2 μM).
-
DescriptionPyroxamide is an histone deacetylases (HDACs) inhibitor with antineoplastic properties ( HDAC1;IC50: 0.1-0.2 μM).
-
In VitroCell Viability Assay Cell Line:RD cells; RH30B cells Concentration:1.25-20.0 μM Incubation Time:24 hours; 48 hours; 72 hours Result:Resulted in a cell growth decrease in RD and RH30B cells.Cell Cycle Analysis Cell Line:RD cells; RH30B cells Concentration:10.0 μM; 20.0 μM Incubation Time:48 hours Result:Increased the sub-G1?fractions at 48 hours compared with control samples.
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number382180-17-8
-
Formula Weight265.31
-
Molecular FormulaC13H19N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:125 mg/mL (471.15 mM)
-
SMILESO=C(CCCCCCC(=O)Nc1cccnc1)NO
-
Chemical NameN1-hydroxy-N8-(pyridin-3-yl)octanediamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Butler L M Webb Y Agus D B et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide an inhibitor of histone deacetylase[J]. Clinical Cancer Research 2001 7(4):962-970.
molnova catalog
related products
-
HDAC1,2-IN-2
A potent, selective HDAC1 and HDAC2 inhibitor with IC50 of 6 nM and 45 nM, respectively.
-
Ledipasvir
Ledipasvir is a Hepatitis C Virus NS5A Inhibitor. The mechanism of action of ledipasvir is as a P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor.
-
HDACi-4b
A benzamide-type HDAC inhibitor with IC50 of 78 uM for changes of FXN mRNA in affected GM15850 cells.
Cart
sales@molnova.com